Copyright
©The Author(s) 2026. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Stem Cells. Jan 26, 2026; 18(1): 114891
Published online Jan 26, 2026. doi: 10.4252/wjsc.v18.i1.114891
Published online Jan 26, 2026. doi: 10.4252/wjsc.v18.i1.114891
Co-expression of cancer stem cell markers CD24 and CD133 in gastric cancer tissues: Clinicopathological and prognostic significance
Cheng-Xian Ma, Xia He, Department of Oncology, The Affiliated Cancer Hospital of Nanjing Medical University, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, Nanjing 210009, Jiangsu Province, China
Cheng-Xian Ma, Yu-Si Xie, Department of Radiation Oncology, Guangxi Medical University Cancer Hospital, Nanning 530012, Guangxi Zhuang Autonomous Region, China
Jie Chen, Department of Oncology, Nanjing Jiangning Hospital, The Affiliated Jiangning Hospital of Nanjing Medical University, Nanjing 210009, Jiangsu Province, China
Jian-Lin Wang, Department of Radiotherapy, The Affiliated Changzhou Second People’s Hospital of Nanjing Medical University, Changzhou 213003, Jiangsu Province, China
Shuai Pei, Department of Interventional Therapy, BenQ Hospital, Nanjing 210026, Jiangsu Province, China
Zhao-Jun Zhang, Department of Oncology, The First People’s Hospital of Qinzhou, Qinzhou 530550, Guangxi Zhuang Autonomous Region, China
Author contributions: Ma CX and Chen J designed the study; Wang JL, Pei S, and Zhang ZJ performed the experiments; Xie YS and He X analyzed the data. All authors contributed to editorial changes in the manuscript. All authors read and approved the final manuscript.
Supported by National Natural Science Foundation of China, No. 82003223; and China Postdoctoral Science Foundation, No. 2020M671398.
Institutional review board statement: This study was approved by the Ethics Committee of Guangxi Medical University Cancer Hospital [Approval No. KJCS2018(13)] and conducted in accordance with the Declaration of Helsinki.
Informed consent statement: All participants signed written informed consent forms.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Data sharing statement: No additional data are available.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Xia He, Full Professor, Department of Oncology, The Affiliated Cancer Hospital of Nanjing Medical University, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, No. 42 Baiziting, Kunlun Road, Nanjing 210009, Jiangsu Province, China.
Received: October 14, 2025
Revised: October 29, 2025
Accepted: December 3, 2025
Published online: January 26, 2026
Processing time: 97 Days and 18.2 Hours
Revised: October 29, 2025
Accepted: December 3, 2025
Published online: January 26, 2026
Processing time: 97 Days and 18.2 Hours
Core Tip
Core Tip: CD24 and CD133 exhibit high positive detection rates in gastric cancer tissues. The co-expression of CD24 and CD133 was closely related to the advanced tumor stage. Co-positivity of CD24 and CD133 predicts poor survival. The co-expression of CD24/CD133 may reflect the higher invasive and metastatic potential of gastric cancer. This combined in